---

---

treatment   publishing date : 2021 - 10 - 12   

save search

---

Corium Receives March 11, 2022 PDUFA Date for New Drug Application for ADLARITY® Patch (donepezil transdermal system) for Treatment of Patients with Alzheimer's Disease
Published: 2021-10-12 (Crawled : 14:15) - biospace.com/
HTGC F | $18.16 0.95% -0.22% 730K |

Finance

| 4.65% | O: -0.06% H: 0.64% C: -0.29%
new drug disease alzheimer treatment pdufa drug alzheimer’s transdermal system alzheimer's disease alzheimer's

---

Hoth Therapeutics Receives Approval to Commence Cohort 2 in Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis Patients
Published: 2021-10-12 (Crawled : 14:00) - ir.hoththerapeutics.com
HOTH | $1.19 -0.83% -0.84% 24K |

Health Technology

| 4.35% | O: 0.0% H: 12.17% C: 0.87%
treatment dermatitis trial approval atopic dermatitis xin

---

Rejuveron leads EUR 15.7 million Series B investment in Rejuvenate Biomed to accelerate clinical development of its sarcopenia treatment for healthy aging
Published: 2021-10-12 (Crawled : 14:00) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M |

Health Technology

| -9.86% | O: -0.16% H: 0.11% C: -1.44%
treatment

---

Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
Published: 2021-10-12 (Crawled : 13:15) - biospace.com/
ATXS | $10.53 -5.14% -5.41% 550K |

Manufacturing

| 50.2% | O: 0.0% H: 5.68% C: 4.47%
disease treatment rare hereditary angioedema

---

Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Published: 2021-10-12 (Crawled : 13:00) - biospace.com/
ALPMY | News | $9.34 -1.11% 690K |

Manufacturing

| -45.96% | O: 2.57% H: 0.0% C: -2.82%
SGEN | $228.74 0.1% 20M |

Health Technology

| 41.07% | O: 0.22% H: 2.27% C: 1.35%
treatment cancer trial enroll

---

Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
Published: 2021-10-12 (Crawled : 12:00) - prnewswire.com
ALPMY | News | $9.34 -1.11% 690K |

Manufacturing

| -45.96% | O: 2.57% H: 0.0% C: -2.82%
SGEN | $228.74 0.1% 20M |

Health Technology

| 41.07% | O: 0.22% H: 2.27% C: 1.35%
treatment cancer trial enroll

---

Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results
Published: 2021-10-12 (Crawled : 12:15) - biospace.com/
WINT | News | $0.3903 -7.4% -7.99% 110K |

Health Technology

| -81.75% | O: 1.3% H: 1.28% C: -2.56%
treatment eye cardiologists results drug research cardio

---

Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
Published: 2021-10-12 (Crawled : 12:00) - globenewswire.com
TARA | $2.75 -3.51% -3.64% 170K |

Health Technology

| -57.78% | O: 15.1% H: 2.33% C: -2.82%
new drug fda clearance treatment fda cancer drug clearance bladder

---

Achilles Therapeutics to join the Northern Alliance Advanced Therapy Treatment Centre consortium
Published: 2021-10-12 (Crawled : 12:00) - globenewswire.com
ACHL | $0.8 -0.27% -0.28% 180K |

Manufacturing

| Email alert Add to watchlist
treatment therapy

---

Deciphera Announces Approval of QINLOCK® in Switzerland for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
Published: 2021-10-12 (Crawled : 12:00) - biospace.com/
DCPH | $14.72 -0.81% -0.82% 300K |

Health Technology

| -54.06% | O: 0.19% H: 7.51% C: 6.61%
treatment test gastrointestinal switzerland approval

---

Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS Study
Published: 2021-10-12 (Crawled : 12:00) - globenewswire.com
WINT | News | $0.3903 -7.4% -7.99% 110K |

Health Technology

| -81.75% | O: 1.3% H: 1.28% C: -2.56%
treatment eye cardiologists results drug research cardio

---

NanoString Launches nCounter Antibody Drug Conjugate Panel to Accelerate the Development of Oncology Treatments
Published: 2021-10-12 (Crawled : 11:00) - biospace.com/
NSTG | News | $0.1053 -37.43% -0.19% 0 |

Health Technology

| -99.75% | O: 1.41% H: 3.59% C: 1.5%
treatment antibody drug

---

Gainers vs Losers

56%

44%

Top 10 Gainers

INVO | $1.76 131.58% 56.82% 230M |

Health Technology

SINT | $0.0365 59.39% 37.26% 470M |

Health Technology

WISA 4 | $9.19 50.66% 33.7% 65M |

Electronic Technology

EDBL | News | $6.73 47.91% 32.39% 13M |

GCTK | $0.715 36.27% 26.62% 640K |

Manufacturing

TCON | $2.33 36.26% 26.61% 2M |

Health Technology

TIRX | $0.48 6.43% 24.58% 4.8M |

KZIA | $0.38 30.58% 23.42% 300K |

Health Technology

VNDA | News | $5.23 29.14% 22.56% 24M |

Health Technology

ATNF | $1.91 29.05% 22.51% 310K |

---

Your saved searches

---